Today: 9 June 2026
UOB share price dips as Singapore bank earnings near; Maybank keeps ‘hold’ call
6 February 2026
2 mins read

UOB share price dips as Singapore bank earnings near; Maybank keeps ‘hold’ call

Singapore, Feb 6, 2026, 15:15 SGT — Regular session

  • UOB was down about 0.4% at S$38.48 in afternoon trade.
  • Analysts are watching whether easing funding pressure can stabilise bank margins into 2026.
  • UOB’s full-year results are due on Feb. 24, with DBS reporting first on Feb. 9.

United Overseas Bank Ltd (UOBH.SI) shares slipped about 0.4% to S$38.48 by mid-afternoon on Friday, after trading between S$38.05 and S$38.60. The stock is near its 52-week high of S$39.50, but risk appetite weakened across Asia after a tech-led selloff on Wall Street.

The move comes as Singapore’s banks head into a February run of earnings, where small shifts in net interest margin — the gap between what a lender earns on loans and pays on deposits — can swing dividend expectations and valuations. Analysts have said signs of “margin relief” are starting to show, but the sector still lacks an obvious next leg of growth. The Business Times

In a Feb. 4 preview note, Maybank Research analyst Thilan Wickramasinghe said the margin squeeze that weighed on earnings over the past year may be easing as funding pressures cool. He kept a “hold” call on UOB, with a target price of S$36.80, below where the stock traded on Friday. Maybank Ke

Singapore’s Straits Times Index was down about 0.7% by the midday break, The Business Times reported, with DBS down about 0.7% and OCBC off roughly 0.9% at the same point.

Wickramasinghe expects a bounce in UOB’s quarterly earnings after what he described as a low base in the third quarter, when credit costs climbed. He pencilled in fourth-quarter earnings of S$1.35 billion to S$1.43 billion, versus S$440 million in the prior quarter, the note showed.

In his view, “SORA contraction is stabilizing” — a nod to the Singapore Overnight Rate Average, a key benchmark for local borrowing costs. He said the hit eased to 27 basis points in the fourth quarter from about 60 basis points in the third; a basis point is one-hundredth of a percentage point.

Maybank also pointed to firmer loan growth and banks cutting deposit rates as factors that could slow net interest margin compression. The note estimated system loan growth of about 5% in 2025, helped by construction, mortgage and small business lending, and said that should help keep net interest income steadier.

Fees are a wilder card. The note flagged seasonally softer wealth management fees in the fourth quarter, but said markets-related income and loan fees could offer support, while UOB could see improved credit card fees after a weak third quarter linked to high reward redemptions in Thailand.

But the downside case is still there. Maybank said UOB’s credit costs surprised higher in the third quarter on pre-emptive provisions tied to commercial real estate exposure, and warned credit costs could remain elevated even if they ease quarter-on-quarter. It also flagged UOB as an outlier on costs as the bank invests in upgrading its retail platform.

The next catalyst is the earnings calendar. DBS is due to report on Feb. 9, with UOB scheduled for Feb. 24 and OCBC for Feb. 25, according to recent analyst previews.

UOB has said it will release its full-year 2025 financial results on Feb. 24 before trading begins. Investors will be watching for dividend signals and guidance that shifts from margin talk to the underlying trajectory of net interest income and credit costs.

Stock Market Today

  • Invest in India’s Top 500 Companies with 3 Low-Cost Index Funds
    June 9, 2026, 10:10 AM EDT. Investors can access India's top 500 companies efficiently through three non-overlapping index funds: Nifty 100 (large-cap), Nifty Midcap 150, and Nifty Smallcap 250. The Nifty 100 Index Fund includes India's top 100 large-cap companies by market capitalization, spanning 17 sectors, and offers resilience in downturns. Common holdings such as HDFC Bank, Reliance Industries, and Infosys provide exposure to key economic sectors. Using these three funds prevents portfolio overlap, ensuring true diversification across market segments. Choices for Nifty 100 Index Funds include Axis, HDFC, and Bandhan, with options for systematic investment plans (SIPs). This strategy offers low cost, broad exposure, and balanced risk for investors seeking diversified growth in Indian equities.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Super Micro (SMCI) stock slides 9% after earnings spike — what to watch before Friday’s trade
Previous Story

Super Micro (SMCI) stock slides 9% after earnings spike — what to watch before Friday’s trade

Ford stock slips before market open as EV sales dive and Geely talks linger
Next Story

Ford stock slips before market open as EV sales dive and Geely talks linger

Go toTop